 Whitney Goldner
Concepts (233)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 17 | 2024 | 312 | 5.110 |
Why?
| | Thyroid Nodule | 4 | 2025 | 56 | 1.260 |
Why?
| | Thyroid Gland | 5 | 2024 | 95 | 1.200 |
Why?
| | Pesticides | 5 | 2019 | 58 | 1.170 |
Why?
| | Thyroidectomy | 7 | 2024 | 89 | 1.060 |
Why?
| | Survivorship | 1 | 2024 | 47 | 0.880 |
Why?
| | Adenocarcinoma | 4 | 2023 | 893 | 0.800 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2024 | 204 | 0.780 |
Why?
| | Hypothyroidism | 3 | 2023 | 70 | 0.760 |
Why?
| | Carcinoma | 3 | 2025 | 214 | 0.760 |
Why?
| | Agriculture | 3 | 2019 | 92 | 0.750 |
Why?
| | Societies, Medical | 4 | 2024 | 744 | 0.750 |
Why?
| | Thyroid Diseases | 3 | 2024 | 35 | 0.700 |
Why?
| | Tumor Microenvironment | 1 | 2024 | 627 | 0.680 |
Why?
| | Vitamin D | 4 | 2012 | 381 | 0.670 |
Why?
| | Cancer Survivors | 1 | 2024 | 257 | 0.660 |
Why?
| | Hyperglycemia | 4 | 2021 | 327 | 0.610 |
Why?
| | Hypophosphatasia | 1 | 2018 | 3 | 0.600 |
Why?
| | Occupational Exposure | 4 | 2019 | 299 | 0.590 |
Why?
| | Agricultural Workers' Diseases | 2 | 2018 | 33 | 0.560 |
Why?
| | Alkaline Phosphatase | 1 | 2018 | 146 | 0.560 |
Why?
| | Hypercalcemia | 1 | 2016 | 21 | 0.510 |
Why?
| | Vitamin D Deficiency | 2 | 2008 | 177 | 0.510 |
Why?
| | Quality of Health Care | 1 | 2020 | 604 | 0.500 |
Why?
| | Neuroendocrine Tumors | 4 | 2021 | 99 | 0.500 |
Why?
| | Paraganglioma | 1 | 2016 | 49 | 0.500 |
Why?
| | Multimodal Imaging | 1 | 2016 | 110 | 0.500 |
Why?
| | Choroid Neoplasms | 1 | 2015 | 8 | 0.480 |
Why?
| | Quality of Life | 2 | 2024 | 2688 | 0.480 |
Why?
| | Recombinant Fusion Proteins | 1 | 2018 | 651 | 0.480 |
Why?
| | Mediastinal Neoplasms | 1 | 2015 | 38 | 0.470 |
Why?
| | Carcinoma, Papillary | 1 | 2015 | 77 | 0.460 |
Why?
| | Testosterone | 1 | 2018 | 372 | 0.460 |
Why?
| | Relaxin | 2 | 2024 | 18 | 0.460 |
Why?
| | Spouses | 2 | 2018 | 101 | 0.440 |
Why?
| | Immunoglobulin G | 1 | 2018 | 851 | 0.430 |
Why?
| | Humans | 52 | 2025 | 129625 | 0.410 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1501 | 0.400 |
Why?
| | Lymph Nodes | 1 | 2015 | 472 | 0.390 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2012 | 151 | 0.380 |
Why?
| | Thyroxine | 1 | 2012 | 62 | 0.380 |
Why?
| | Adrenal Insufficiency | 2 | 2023 | 32 | 0.370 |
Why?
| | Neoplasms | 4 | 2024 | 2455 | 0.360 |
Why?
| | Hormone Replacement Therapy | 1 | 2012 | 93 | 0.360 |
Why?
| | Middle Aged | 19 | 2024 | 31136 | 0.340 |
Why?
| | Adult | 22 | 2024 | 35599 | 0.320 |
Why?
| | Biomarkers, Tumor | 4 | 2024 | 1164 | 0.320 |
Why?
| | Gastric Bypass | 2 | 2008 | 108 | 0.310 |
Why?
| | Adrenal Gland Neoplasms | 2 | 2021 | 83 | 0.310 |
Why?
| | Vitamins | 2 | 2010 | 173 | 0.290 |
Why?
| | Medical Oncology | 3 | 2021 | 269 | 0.290 |
Why?
| | Body Weight | 1 | 2012 | 940 | 0.280 |
Why?
| | Obesity, Morbid | 2 | 2008 | 241 | 0.280 |
Why?
| | Iodine Radioisotopes | 3 | 2022 | 142 | 0.250 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2024 | 232 | 0.240 |
Why?
| | Aged | 10 | 2024 | 22061 | 0.240 |
Why?
| | Hypoglycemic Agents | 2 | 2011 | 1221 | 0.230 |
Why?
| | Iowa | 3 | 2018 | 24 | 0.230 |
Why?
| | Blood Glucose | 6 | 2021 | 2100 | 0.230 |
Why?
| | North Carolina | 3 | 2018 | 98 | 0.230 |
Why?
| | Endocrine System Diseases | 1 | 2024 | 33 | 0.220 |
Why?
| | Monitoring, Ambulatory | 1 | 2004 | 83 | 0.210 |
Why?
| | Insulin Resistance | 2 | 2011 | 1167 | 0.210 |
Why?
| | Menstrual Cycle | 1 | 2004 | 121 | 0.210 |
Why?
| | Hypophysitis | 1 | 2023 | 3 | 0.210 |
Why?
| | Cholecalciferol | 2 | 2014 | 56 | 0.200 |
Why?
| | Adenoma | 1 | 2025 | 214 | 0.200 |
Why?
| | Male | 19 | 2024 | 63670 | 0.200 |
Why?
| | Iodine | 1 | 2022 | 24 | 0.200 |
Why?
| | Lung Neoplasms | 1 | 2015 | 2342 | 0.190 |
Why?
| | B7-H1 Antigen | 1 | 2024 | 198 | 0.190 |
Why?
| | Female | 20 | 2024 | 68734 | 0.190 |
Why?
| | Thyroid Carcinoma, Anaplastic | 1 | 2022 | 35 | 0.190 |
Why?
| | Bone Diseases, Metabolic | 1 | 2002 | 57 | 0.190 |
Why?
| | Retrospective Studies | 9 | 2025 | 14522 | 0.190 |
Why?
| | Urticaria | 2 | 2014 | 37 | 0.190 |
Why?
| | Insulin | 2 | 2011 | 2326 | 0.180 |
Why?
| | Asthenia | 1 | 2021 | 2 | 0.180 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2024 | 373 | 0.180 |
Why?
| | Prospective Studies | 7 | 2021 | 7135 | 0.180 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2023 | 181 | 0.170 |
Why?
| | Postoperative Care | 2 | 2015 | 241 | 0.170 |
Why?
| | Radiation-Protective Agents | 1 | 2019 | 26 | 0.160 |
Why?
| | Metalloporphyrins | 1 | 2019 | 101 | 0.160 |
Why?
| | Colonic Neoplasms | 1 | 2021 | 242 | 0.160 |
Why?
| | Hyperthyroidism | 1 | 2019 | 28 | 0.160 |
Why?
| | Lutein | 1 | 2019 | 14 | 0.160 |
Why?
| | Zeaxanthins | 1 | 2019 | 18 | 0.160 |
Why?
| | United States | 5 | 2024 | 13871 | 0.150 |
Why?
| | Radiopharmaceuticals | 1 | 2019 | 168 | 0.150 |
Why?
| | Kidney Neoplasms | 1 | 2023 | 348 | 0.150 |
Why?
| | Chromatography, Liquid | 2 | 2018 | 423 | 0.150 |
Why?
| | DNA Mutational Analysis | 1 | 2019 | 382 | 0.150 |
Why?
| | Radioimmunoassay | 1 | 2018 | 175 | 0.150 |
Why?
| | Capital Financing | 1 | 2017 | 7 | 0.140 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1203 | 0.140 |
Why?
| | Patient Reported Outcome Measures | 1 | 2021 | 374 | 0.140 |
Why?
| | Training Support | 1 | 2017 | 28 | 0.140 |
Why?
| | Mutation | 2 | 2019 | 3717 | 0.140 |
Why?
| | Maternal Nutritional Physiological Phenomena | 1 | 2019 | 169 | 0.130 |
Why?
| | Hospitals, Teaching | 1 | 2017 | 114 | 0.130 |
Why?
| | Age Factors | 1 | 2024 | 3152 | 0.130 |
Why?
| | Succinate Dehydrogenase | 1 | 2016 | 45 | 0.130 |
Why?
| | Macrophages | 1 | 2024 | 1488 | 0.130 |
Why?
| | Fetal Blood | 1 | 2019 | 317 | 0.130 |
Why?
| | Follow-Up Studies | 4 | 2024 | 4894 | 0.130 |
Why?
| | Melanoma | 1 | 2023 | 730 | 0.130 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2018 | 248 | 0.120 |
Why?
| | Transplantation | 1 | 2015 | 31 | 0.120 |
Why?
| | Risk Assessment | 1 | 2024 | 3262 | 0.120 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 958 | 0.120 |
Why?
| | Cell Line, Tumor | 3 | 2024 | 3186 | 0.120 |
Why?
| | Universities | 1 | 2017 | 409 | 0.120 |
Why?
| | Mass Spectrometry | 1 | 2018 | 714 | 0.110 |
Why?
| | Diabetes Mellitus | 2 | 2021 | 1001 | 0.110 |
Why?
| | Genetic Variation | 1 | 2019 | 939 | 0.110 |
Why?
| | Sepsis | 1 | 2020 | 575 | 0.110 |
Why?
| | Neoplasm Metastasis | 1 | 2016 | 611 | 0.110 |
Why?
| | DNA Adducts | 1 | 2013 | 16 | 0.110 |
Why?
| | Postoperative Complications | 2 | 2021 | 2477 | 0.100 |
Why?
| | Education, Medical, Graduate | 1 | 2017 | 442 | 0.100 |
Why?
| | Pilot Projects | 2 | 2008 | 1592 | 0.100 |
Why?
| | Obesity | 2 | 2004 | 2882 | 0.100 |
Why?
| | Cholestanetriol 26-Monooxygenase | 1 | 2012 | 7 | 0.100 |
Why?
| | Steroid Hydroxylases | 1 | 2012 | 22 | 0.100 |
Why?
| | Vitamin D3 24-Hydroxylase | 1 | 2012 | 15 | 0.100 |
Why?
| | Cytochrome P450 Family 2 | 1 | 2012 | 12 | 0.100 |
Why?
| | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2012 | 17 | 0.100 |
Why?
| | TATA-Box Binding Protein | 1 | 2012 | 20 | 0.100 |
Why?
| | Receptors, G-Protein-Coupled | 2 | 2024 | 207 | 0.100 |
Why?
| | Calcitriol | 1 | 2012 | 54 | 0.100 |
Why?
| | Prevalence | 2 | 2010 | 2564 | 0.100 |
Why?
| | Triiodothyronine | 1 | 2011 | 44 | 0.090 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2012 | 285 | 0.090 |
Why?
| | Signal Transduction | 1 | 2024 | 4931 | 0.090 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2021 | 2442 | 0.090 |
Why?
| | Diet | 1 | 2019 | 1213 | 0.090 |
Why?
| | Environmental Exposure | 2 | 2018 | 463 | 0.090 |
Why?
| | Estrogens | 1 | 2013 | 347 | 0.090 |
Why?
| | Fumigation | 1 | 2010 | 3 | 0.080 |
Why?
| | Fungicides, Industrial | 1 | 2010 | 6 | 0.080 |
Why?
| | Antimicrobial Cationic Peptides | 1 | 2010 | 77 | 0.080 |
Why?
| | Herbicides | 1 | 2010 | 23 | 0.080 |
Why?
| | Dietary Supplements | 1 | 2014 | 534 | 0.080 |
Why?
| | Hypoglycemia | 1 | 2014 | 427 | 0.080 |
Why?
| | Treatment Outcome | 3 | 2018 | 10219 | 0.080 |
Why?
| | Surveys and Questionnaires | 3 | 2019 | 5415 | 0.080 |
Why?
| | Hyperparathyroidism, Secondary | 1 | 2008 | 12 | 0.070 |
Why?
| | Parathyroid Hormone | 1 | 2008 | 107 | 0.070 |
Why?
| | Depressive Disorder, Major | 1 | 2011 | 345 | 0.070 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2004 | 3628 | 0.070 |
Why?
| | Internship and Residency | 1 | 2017 | 1050 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2012 | 2011 | 0.070 |
Why?
| | Neoplasm Staging | 3 | 2018 | 1282 | 0.070 |
Why?
| | Dermatitis, Atopic | 1 | 2010 | 319 | 0.070 |
Why?
| | Creatinine | 1 | 2008 | 490 | 0.070 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2012 | 1336 | 0.060 |
Why?
| | Hospitalization | 1 | 2015 | 2057 | 0.060 |
Why?
| | Cell Proliferation | 1 | 2012 | 2373 | 0.060 |
Why?
| | Logistic Models | 1 | 2010 | 1986 | 0.060 |
Why?
| | Biopsy, Fine-Needle | 1 | 2024 | 67 | 0.060 |
Why?
| | Receptors, Peptide | 1 | 2024 | 17 | 0.060 |
Why?
| | Cross-Sectional Studies | 2 | 2019 | 5075 | 0.060 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2024 | 59 | 0.060 |
Why?
| | Inpatients | 2 | 2021 | 475 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 1 | 2015 | 3394 | 0.050 |
Why?
| | Weight Loss | 1 | 2008 | 738 | 0.050 |
Why?
| | Incidence | 2 | 2021 | 2641 | 0.050 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2004 | 374 | 0.050 |
Why?
| | Anastomosis, Roux-en-Y | 1 | 2002 | 27 | 0.050 |
Why?
| | CTLA-4 Antigen | 1 | 2023 | 87 | 0.050 |
Why?
| | Gastroplasty | 1 | 2002 | 29 | 0.050 |
Why?
| | Hormones | 1 | 2023 | 141 | 0.050 |
Why?
| | Thyroglobulin | 1 | 2022 | 27 | 0.050 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2022 | 32 | 0.050 |
Why?
| | Calcium | 1 | 2008 | 1212 | 0.050 |
Why?
| | C-Reactive Protein | 1 | 2004 | 400 | 0.050 |
Why?
| | Antigens, CD | 1 | 2024 | 487 | 0.050 |
Why?
| | Risk Factors | 4 | 2019 | 9786 | 0.050 |
Why?
| | Ultrasonography | 1 | 2025 | 712 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 2010 | 2542 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2025 | 1432 | 0.040 |
Why?
| | Radiography | 1 | 2002 | 797 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2024 | 1843 | 0.040 |
Why?
| | Salivary Glands | 1 | 2019 | 29 | 0.040 |
Why?
| | Genomics | 1 | 2024 | 718 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2024 | 1947 | 0.040 |
Why?
| | Beta-Cryptoxanthin | 1 | 2019 | 1 | 0.040 |
Why?
| | beta Carotene | 1 | 2019 | 21 | 0.040 |
Why?
| | Xanthophylls | 1 | 2019 | 18 | 0.040 |
Why?
| | Carotenoids | 1 | 2019 | 41 | 0.040 |
Why?
| | Image-Guided Biopsy | 1 | 2018 | 37 | 0.040 |
Why?
| | Diet Surveys | 1 | 2019 | 92 | 0.040 |
Why?
| | Immunotherapy | 1 | 2023 | 596 | 0.040 |
Why?
| | Glucocorticoids | 1 | 2023 | 580 | 0.040 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2018 | 210 | 0.030 |
Why?
| | Young Adult | 3 | 2019 | 12455 | 0.030 |
Why?
| | Chronic Disease | 2 | 2014 | 1720 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1198 | 0.030 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2021 | 601 | 0.030 |
Why?
| | Patient Readmission | 1 | 2021 | 653 | 0.030 |
Why?
| | Cetirizine | 1 | 2014 | 2 | 0.030 |
Why?
| | Ranitidine | 1 | 2014 | 14 | 0.030 |
Why?
| | Cyclopropanes | 1 | 2014 | 89 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 1005 | 0.030 |
Why?
| | Acetates | 1 | 2014 | 100 | 0.030 |
Why?
| | Sulfides | 1 | 2014 | 95 | 0.030 |
Why?
| | Quinolines | 1 | 2014 | 156 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2018 | 887 | 0.020 |
Why?
| | Placenta | 1 | 2019 | 723 | 0.020 |
Why?
| | Medicare | 1 | 2017 | 708 | 0.020 |
Why?
| | Disease Management | 1 | 2015 | 588 | 0.020 |
Why?
| | Cathelicidins | 1 | 2010 | 37 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 3774 | 0.020 |
Why?
| | Animals | 2 | 2024 | 35391 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2013 | 523 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 1560 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2019 | 5455 | 0.020 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2011 | 253 | 0.020 |
Why?
| | Administration, Oral | 1 | 2010 | 787 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2019 | 5756 | 0.020 |
Why?
| | Disease Progression | 1 | 2014 | 2627 | 0.020 |
Why?
| | Pregnancy | 1 | 2019 | 6417 | 0.020 |
Why?
| | Adolescent | 1 | 2004 | 20412 | 0.010 |
Why?
| | Glyburide | 1 | 2004 | 35 | 0.010 |
Why?
| | Leptin | 1 | 2004 | 220 | 0.010 |
Why?
| | Adiponectin | 1 | 2004 | 235 | 0.010 |
Why?
| | Cross-Over Studies | 1 | 2004 | 520 | 0.010 |
Why?
| | Linear Models | 1 | 2004 | 819 | 0.010 |
Why?
| | Metformin | 1 | 2004 | 318 | 0.010 |
Why?
| | Lipids | 1 | 2004 | 627 | 0.010 |
Why?
| | Body Composition | 1 | 2004 | 649 | 0.010 |
Why?
| | Sex Factors | 1 | 2004 | 1970 | 0.010 |
Why?
|
|
Goldner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|